BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas Noémie Leblay,

Slides:

Advertisements

Similar presentations

Hippo Pathway Gene Mutations in Malignant Mesothelioma: Revealed by RNA and Targeted Exon Sequencing Akihiko Miyanaga, MD, PhD, Mari Masuda, PhD, Koji.

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study Marco Lo Iacono, PhD, Valentina.

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

EGFR and KRAS Mutations in Triple-Mutated Lung Cancer

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases Åslaug Helland, MD, PhD, Steinar Solberg,

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma Bibhusal Thapa, FCPS, Adriana Salcedo, MSc, Xihui Lin,

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival Zarah Glad.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Improving the Accuracy of Mesothelioma Diagnosis in China

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non–Small Cell Lung Cancer from Adjuvant Cisplatin–Based Therapy Randomized Trials: A.

An Unusual Presentation of Malignant Pleural Mesothelioma

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis Fraser J.H. Brims, MD, Tarek M. Meniawy,

The Oncofetal Protein IMP3: A Useful Marker to Predict Poor Clinical Outcome in Neuroendocrine Tumors of the Lung Alessandro Del Gobbo, MD, Valentina.

Genetic Variation in GSTP1, Lung Function, Risk of Lung Cancer, and Mortality Marianne S. Nørskov, MSc, PhD, Morten Dahl, MD, DMSc, Anne Tybjærg-Hansen,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization Serena Varesano, PhD, Sandra Salvi, PhD, Simona Boccardo, PhD, Jean.

BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study Gunnar Hillerdal, MD, PhD, Jens.

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Mitotic Inhibitors Journal of Thoracic Oncology

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma Loïc.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD

Robert Comis, MD, The Passing of a “Lung Man”

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas Noémie Leblay, MSc, Frédéric Leprêtre, PhD, Nolwenn Le Stang, MSc, Amandine Gautier-Stein, PhD, Laurent Villeneuve, MSc, Sylvie Isaac, MD, Denis Maillet, MD, Françoise Galateau-Sallé, MD, PhD, Céline Villenet, BS, Shéhérazade Sebda, BS, Alexandra Goracci, MD, Graham Byrnes, PhD, James D McKay, PhD, Martin Figeac, PhD, Olivier Glehen, MD, PhD, François-Noël Gilly, MD, PhD, Matthieu Foll, PhD, Lynnette Fernandez-Cuesta, PhD, Marie Brevet, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 4, Pages 724-733 (April 2017) DOI: 10.1016/j.jtho.2016.12.019 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Overview of BAP1 status in malignant peritoneal mesothelioma. (A) Distribution of BRCA1 associated protein 1 gene (BAP1) mutations across the different protein domains. The height of the blue bars correlates with the frequency of the observed mutation. (B) Overview of BAP1 alterations detected in the 46 peritoneal mesotheliomas. Gray means that data are not available. (C) Examples of negative (left panel) and positive (right panel) staining for BRCA1 associated protein 1 (BAP1) nuclear expression in two peritoneal mesotheliomas. HCF1, host cell factor C1; ID, identifier. Journal of Thoracic Oncology 2017 12, 724-733DOI: (10.1016/j.jtho.2016.12.019) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Survival analyses. (A) Cox proportional hazards regression for BRCA1 associated protein 1 (BAP1) nuclear expression and histological type. (B) Cox proportional hazards regression for BRCA1 associated protein 1 gene (BAP1) mutation and histological type. (C) Cox proportional hazards regression for BAP1 nuclear expression and/or BAP1 mutation and histological type. EMM, epithelial malignant mesothelioma; MM, malignant mesothelioma; CI95%, 95% confidence limit; HR, hazard ratio. Journal of Thoracic Oncology 2017 12, 724-733DOI: (10.1016/j.jtho.2016.12.019) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions